Browsing: Amgen

Amgen Inc. (ISIN US0311621009) stock is trading close to its recent level in mid-August 2026 as investors weigh a higher analyst price target against a strategic reset in the company’s obesity drug pipeline, highlighted on August 17, 2026 by new industry reporting. One recent note lifted the 12?month price objective on Amgen shares to $380,…

Amgen (NASDAQ:AMGN), the biotech heavyweight behind treatments for cancer, cardiovascular disease and other serious illnesses, gave investors another reason to cheer after posting a stronger-than-expected second quarter. Reuters reported revenue climbed 9% year over year to about $10.05 billion, while adjusted earnings landed at $6.29 per share, comfortably ahead of the $5.62 Wall Street consensus.…

Russell 1000LLYNVOAMGNPFEABBV 11 min read | July 27, 2026 02:28 PM PDT | By Anmol Khazanchi Google News:

The world’s biggest YouTuber is using his platform to bring hope to children living with cancer. Here’s how Amgen is helping advance the research behind that hope

Amgen stock sits at the intersection of mature biologic franchises and a broad late-stage pipeline that is increasingly focused on oncology and cardiometabolic diseases. The California-based biotechnology group Amgen Inc. (ISIN US0311621009) combines steady cash generation from legacy drugs such as Enbrel and Prolia with new assets in cancer and obesity, giving investors a blend…

Amgen Inc. (ISIN US0311621009) stock sits in the large-cap pharma bracket with investors closely watching how recent double-digit revenue growth and the integration of Horizon Therapeutics translate into future earnings power. In 2023 Amgen reported revenue of roughly $28.2 billion, up around 7% from about $26.3 billion in 2022, while the company continued to return…

The pressure on Amgen’s Tavneos is ratcheting up ahead of a potential hearing about the future of the drug. Since the FDA proposed withdrawing approval in April, a journal has retracted a key paper on the rare disease drug, the European Medicines Agency has recommended revoking authorization and Amgen’s Japanese partner has reportedly urged doctors…